News Releases

View printer-friendly version < < back
Johnson & Johnson Reports 2021 First-Quarter Results:
Apr 20, 2021
- 2021 First Quarter Sales of $22.3 Billion reflecting strong growth of 7.9%, operational growth of 5.5%* and adjusted operational growth of 6.0%*
- 2021 First Quarter EPS of $2.32 increased 6.9%; adjusted EPS of $2.59 increased 12.6%*
- Company increased 2021 Full-Year guidance for adjusted operational sales growth to 9.3%* and adjusted operational EPS growth to 16.8%* at the midpoint

NEW BRUNSWICK, N.J., April 20, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2021. "Johnson & Johnson delivered a strong first quarter performance led by the above market growth of our Pharmaceutical business and continued recovery in Medical Devices," said Alex Gorsky, Chairman and Chief Executive Officer. "The ability to deliver these results while simultaneously advancing our robust pipeline of life-enhancing medicines, products and solutions during these times is a testament to the strength and resilience of our business and the dedication of the 135,000 employees of Johnson & Johnson who strive every day to profoundly change the trajectory of health for humanity and make healthier communities for everyone, everywhere."

OVERALL FINANCIAL RESULTS: 

 

FIRST QUARTER

 

($ in Millions, except EPS)

2021

2020

%  Change

Reported Sales

$        22,321

$        20,691

7.9%

Net Earnings

6,197

5,796

6.9

EPS (diluted)

$            2.32

$            2.17

6.9%

       

Non-GAAP*

FIRST QUARTER

 

($ in Millions, except EPS)

2021

2020

%  Change

Operational Sales1,2

   

5.5%

Adjusted Operational Sales1,3

   

6.0

Adjusted Net Earnings1,4

6,924

6,154

12.5

Adjusted EPS (diluted)1,4

$            2.59

$            2.30

12.6%

   

1

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules 

2

Excludes the impact of translational currency

3

Excludes the net impact of acquisitions and divestitures and translational currency

4

Excludes intangible amortization expense and special items

REGIONAL SALES RESULTS: 

 

FIRST QUARTER

%  Change

  

 

($ in Millions)

2021

2020


Reported


Operational1,2


Currency

Adjusted
Operational1,3

U.S.

$        11,111

$        10,699

3.9%

3.9

-

3.9

International

11,210

9,992

12.2

7.3

4.9

8.2

Worldwide

$        22,321

$        20,691

7.9%

5.5

2.4

6.0

   

1

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

2

Excludes the impact of translational currency

3

Excludes the net impact of acquisitions and divestitures and translational currency

 

Note: values may have been rounded

SEGMENT SALES RESULTS:

 

FIRST QUARTER

%  Change

($ in Millions)

2021

2020


Reported


Operational1,2


Currency

Adjusted
Operational1,3

Consumer Health

$          3,543

$          3,625

(2.3)%

(3.3)

1.0

(2.9)

Pharmaceutical

12,199

11,134

9.6

7.1

2.5

7.4

Medical Devices

6,579

5,932

10.9

8.0

2.9

8.8

Worldwide

$        22,321

$        20,691

7.9%

5.5

2.4

6.0

   

 1

Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules

 2

Excludes the impact of translational currency

 3

Excludes the net impact of acquisitions and divestitures and translational currency

 

Note: values may have been rounded

FIRST-QUARTER 2021 SEGMENT COMMENTARY:

Consumer Health
Consumer Health worldwide operational sales, excluding the net impact of acquisitions and divestitures, declined 2.9%* primarily driven by negative prior year comparisons related to the COVID-19 pantry loading in Q1 2020, mainly in over-the counter products.  Partially offsetting the decline is growth in LISTERINE in oral care products, JOHNSON'S BABY in baby care products, international skin health/beauty products and NICORETTE in international over-the-counter products.

Pharmaceutical
Pharmaceutical worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 7.4%* driven by DARZALEX (daratumumab), for the treatment of multiple myeloma, STELARA (ustekinumab), a biologic for the treatment of a number of immune-mediated inflammatory diseases, ERLEADA (apalutamide), a next-generation androgen receptor inhibitor for the treatment of patients with prostate cancer, TREMFYA (guselkumab), a biologic for the treatment of adults living with moderate to severe plaque psoriasis, and for adults with active psoriatic arthritis,  INVEGA SUSTENNA/XEPLION/INVEGA TRINZA/TREVICTA (paliperidone palmitate), long-acting, injectable atypical antipsychotics for the treatment of schizophrenia in adults, IMBRUVICA (ibrutinib), an oral, once-daily therapy approved for use in treating certain B-cell malignancies, a type of blood or lymph node cancer. This growth was partially offset by biosimilar and generic competition, with declines primarily in REMICADE (infliximab), a biologic approved for the treatment of a number of immune-mediated inflammatory diseases, and U.S. ZYTIGA (abiraterone acetate), an oral, once-daily medication for use in combination with prednisone for the treatment of metastatic castration-resistant prostate cancer.

Medical Devices
Medical Devices worldwide operational sales, excluding the net impact of acquisitions and divestitures, grew 8.8%*, and reflects the benefit of market recovery from COVID-19 impacts in the prior year. Contributors to growth were electrophysiology products in the Interventional Solutions business, worldwide biosurgery and energy products, and international endocutters in Advanced Surgery, wound closure products in General Surgery, contact lenses and surgery in the Vision business and trauma products in Orthopaedics; partially offset by knee products in Orthopaedics.

NOTABLE NEW ANNOUNCEMENTS IN THE QUARTER:  
The information contained in this section should be read in conjunction with Johnson & Johnson's other disclosures filed with the Securities and Exchange Commission, including its Current Reports on Form 8-K, Quarterly Reports on Form 10-Q and Annual Reports on Form 10-K. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. The reader is also encouraged to review all other news releases available online in the Investors section of the company's website at news releases.

Regulatory
Decisions

PONVORY (ponesimod) approved by U.S. FDA, an oral treatment for adults with relapsing
multiple sclerosis proven superior to (teriflunomide) in reducing annual relapses and brain
lesions

(press release)

Johnson & Johnson Single-Shot COVID-19 Vaccine granted conditional marketing
authorization by European Commission

(press release)

Johnson & Johnson Single-Shot COVID-19 Vaccine granted emergency use listing by the
World Health Organization

(press release)

Johnson & Johnson COVID-19 Vaccine authorized by U.S. FDA for emergency use

(press release)

SPRAVATO (Esketamine Nasal Spray) authorized in Europe for the rapid reduction of
depressive symptoms in a psychiatric emergency for patients with major depressive disorder

(press release)

MONOFOCAL INTRAOCULAR LENS - TECNIS EYHANCE AND TECNIS EYHANCE
TORIC II IOLS - receives FDA approval for a next generation treatment for cataract patients

(press release)

Regulatory
Submission

Submission of supplemental new drug application to U.S. FDA by ViiV Healthcare for
expanded use of CABENUVA (rilpivirine and cabotegravir) as an HIV treatment for use
every two months

(press release)

Other

Janssen provides update on Phase 3 ACIS Study in patients with metastatic castration-
resistant prostate cancer treated with ERLEADA (apalutamide) and ZYTIGA (abiraterone
acetate) plus prednisone combination ¹

(press release)

Johnson & Johnson announces advance purchase agreement with the African Vaccine
Acquisition Trust for the Company's COVID-19 vaccine candidate

(press release)

PONVORY (ponesimod) receives positive CHMP opinion for the treatment of adults with
relapsing forms of multiple sclerosis with active disease defined by clinical or imaging features

(press release)

CAR-T Therapy Ciltacabtagene Autoleucel (Cilta-cel) accepted for accelerated assessment
in Europe for the treatment of patients with heavily pretreated multiple myeloma

(press release)

1 Subsequent to the quarter

FULL-YEAR 2021 GUIDANCE:
Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

($ in Billions, except EPS)

January 2021

April 2021

Adjusted Operational Sales1,2

Change vs. Prior Year

8.0% - 9.5%

8.7% - 9.9%

Operational Sales2

Change vs. Prior Year

$88.8B - $90.0B

7.5% – 9.0%

$89.3B - $90.3B

8.2% – 9.4%

Estimated Reported Sales3

Change vs. Prior Year

$90.5B - $91.7B

 9.5% – 11.0%

$90.6B - $91.6B

9.7% – 10.9%

     

Adjusted Operational EPS (Diluted)2,4

Change vs. Prior Year

$9.25 - $9.45

15.2% - 17.7%

$9.30 - $9.45

15.8% - 17.7%

Adjusted EPS (Diluted)3,4

Change vs. Prior Year

$9.40 - $9.60

17.1% - 19.6%

$9.42 - $9.57

17.3% - 19.2%

   

1 

Non-GAAP financial measure; excludes the net impact of acquisitions and divestitures

2 

Non-GAAP financial measure; excludes the impact of translational currency

3 

Calculated using Euro Average Rate: January 2021 = $1.21 and April 2021 = $1.19 (Illustrative purposes only)

Non-GAAP financial measure; excludes intangible amortization expense and special items

Other modeling considerations will be provided on the webcast.

WEBCAST INFORMATION:
Johnson & Johnson will conduct a conference call with investors to discuss this earnings release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the call for investors and other interested parties may be accessed by visiting the Johnson & Johnson website. A replay and podcast will be available approximately two hours after the live webcast in the Investors section of the company's website at events-and-presentations

ABOUT JOHNSON & JOHNSON:
At Johnson & Johnson, we believe good health is the foundation of vibrant lives, thriving communities and forward progress. That's why for more than 130 years, we have aimed to keep people well at every age and every stage of life. Today, as the world's largest and most broadly-based health care company, we are committed to using our reach and size for good. We strive to improve access and affordability, create healthier communities, and put a healthy mind, body and environment within reach of everyone, everywhere. We are blending our heart, science and ingenuity to profoundly change the trajectory of health for humanity. 

NON-GAAP FINANCIAL MEASURES:
*Operational sales growth excluding the impact of translational currency, adjusted operational sales growth excluding the net impact of acquisitions and divestitures and translational currency, as well as adjusted net earnings, adjusted diluted earnings per share and adjusted operational diluted earnings per share excluding after-tax intangible amortization expense and special items, are non-GAAP financial measures and should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Except for guidance measures, reconciliations of these non-GAAP financial measures to the most directly comparable GAAP financial measures can be found in the accompanying financial schedules of the earnings release and the Investors section of the company's website at quarterly-results.

Copies of the financial schedules accompanying this earnings release are available on the company's website at quarterly-results. These schedules include supplementary sales data, a condensed consolidated statement of earnings, reconciliations of non-GAAP financial measures, and sales of key products/franchises. Additional information on Johnson & Johnson, including adjusted income before tax by segment, a pharmaceutical pipeline of selected compounds in late stage development and a copy of today's earnings call presentation can also be found in the Investors section of the company's website at quarterly-results.

NOTE TO INVESTORS CONCERNING FORWARD-LOOKING STATEMENTS:
This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding, among other things: future operating and financial performance, product development, market position and business strategy. The reader is cautioned not to rely on these forward-looking statements. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or known or unknown risks or uncertainties materialize, actual results could vary materially from the expectations and projections of Johnson & Johnson. Risks and uncertainties include, but are not limited to: risks related to the impact of the COVID-19 global pandemic, such as the scope and duration of the outbreak, government actions and restrictive measures implemented in response, material delays and cancellations of medical procedures, supply chain disruptions and other impacts to the business, or on the Company's ability to execute business continuity plans, as a result of the COVID-19 pandemic, economic factors, such as interest rate and currency exchange rate fluctuations; competition, including technological advances, new products and patents attained by competitors; challenges inherent in new product research and development, including uncertainty of clinical success and obtaining regulatory approvals; uncertainty of commercial success for new and existing products; challenges to patents; the impact of patent expirations; the ability of the Company to successfully execute strategic plans; the impact of business combinations and divestitures; manufacturing difficulties or delays, internally or within the supply chain; product efficacy or safety concerns resulting in product recalls or regulatory action; significant adverse litigation or government action, including related to product liability claims; changes to applicable laws and regulations, including tax laws and global health care reforms; trends toward health care cost containment; changes in behavior and spending patterns of purchasers of health care products and services; financial instability of international economies and legal systems and sovereign risk; increased scrutiny of the health care industry by government agencies. A further list and descriptions of these risks, uncertainties and other factors can be found in Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2021 including in the sections captioned "Cautionary Note Regarding Forward-Looking Statements" and "Item 1A. Risk Factors," in the Company's most recently filed Quarterly Report on Form 10-Q and the Company's subsequent filings with the Securities and Exchange Commission. Copies of these filings are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Any forward-looking statement made in this release speaks only as of the date of this release. Johnson & Johnson does not undertake to update any forward-looking statement as a result of new information or future events or developments.

Johnson & Johnson and Subsidiaries

                   

Supplementary Sales Data

                   
                     

(Unaudited; Dollars in Millions)

 

FIRST QUARTER

           

 Percent Change

   

2021

 

2020

 

Total

 

Operations

 

Currency

Sales to customers by

                   

segment of business

                   
                     

Consumer Health

                   

    U.S.

 

$     1,611

 

1,740

 

(7.4)

%

(7.4)

 

-

    International

 

1,932

 

1,885

 

2.5

 

0.5

 

2.0

   

3,543

 

3,625

 

(2.3)

 

(3.3)

 

1.0

                     

Pharmaceutical

                   

    U.S.

 

6,446

 

6,061

 

6.4

 

6.4

 

-

    International

 

5,753

 

5,073

 

13.4

 

7.9

 

5.5

   

12,199

 

11,134

 

9.6

 

7.1

 

2.5

                     

Medical Devices

                   

    U.S.

 

3,054

 

2,898

 

5.4

 

5.4

 

-

    International

 

3,525

 

3,034

 

16.2

 

10.5

 

5.7

   

6,579

 

5,932

 

10.9

 

8.0

 

2.9

                     

U.S.

 

11,111

 

10,699

 

3.9

 

3.9

 

-

International

 

11,210

 

9,992

 

12.2

 

7.3

 

4.9

Worldwide

 

$   22,321

 

20,691

 

7.9

%

5.5

 

2.4

                     

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

       

 

 

Johnson & Johnson and Subsidiaries

                 

Supplementary Sales Data

                 
                   

(Unaudited; Dollars in Millions)

FIRST QUARTER

         

Percent Change

 

2021

 

2020

 

Total

 

Operations

 

Currency

Sales to customers by

                 

geographic area

                 
                   

U.S.

$    11,111

 

10,699

 

3.9

%

3.9

 

-

                   

Europe

5,414

 

4,827

 

12.1

 

4.7

 

7.4

Western Hemisphere excluding U.S.

1,424

 

1,502

 

(5.1)

 

0.0

 

(5.1)

Asia-Pacific, Africa

4,372

 

3,663

 

19.4

 

13.7

 

5.7

International

11,210

 

9,992

 

12.2

 

7.3

 

4.9

                   

Worldwide

$    22,321

 

20,691

 

7.9

%

5.5

 

2.4

                   

Note: Percentages have been calculated using actual, non-rounded figures and, therefore, may not recalculate precisely.

 

 

 

Johnson & Johnson and Subsidiaries

                 

Condensed Consolidated Statement of Earnings 

                 
                   

(Unaudited; in Millions Except Per Share Figures)

FIRST QUARTER

                   
 

2021

 

2020

 

Percent

     

Percent

     

Percent

 

Increase

 

Amount

 

to Sales

 

Amount

 

to Sales

 

(Decrease)

Sales to customers

$      22,321

 

100.0

 

$      20,691

 

100.0

 

7.9

Cost of products sold

7,063

 

31.7

 

7,062

 

34.1

 

0.0

Gross Profit

15,258

 

68.3

 

13,629

 

65.9

 

12.0

Selling, marketing and administrative expenses

5,432

 

24.3

 

5,203

 

25.1

 

4.4

Research and development expense

3,178

 

14.2

 

2,580

 

12.5

 

23.2

Interest (income) expense, net

48

 

0.2

 

(42)

 

(0.2)

   

Other (income) expense, net

(882)

 

(3.9)

 

(679)

 

(3.3)

   

Restructuring

53

 

0.2

 

58

 

0.3

   

Earnings before provision for taxes on income

7,429

 

33.3

 

6,509

 

31.5

 

14.1

Provision for taxes on income

1,232

 

5.5

 

713

 

3.5

 

72.8

Net earnings

6,197

 

27.8

 

5,796

 

28.0

 

6.9

                   

Net earnings per share (Diluted)

$          2.32

     

$          2.17

     

6.9

                   

Average shares outstanding (Diluted)

2,672.7

     

2,671.0

       
                   

Effective tax rate

16.6

%

   

11.0

%

     
                   

Adjusted earnings before provision for taxes and net earnings (1)

                 

Earnings before provision for taxes on income

$        8,291

 

37.1

 

$        7,244

 

35.0

 

14.5

Net earnings

$        6,924

 

31.0

 

$        6,154

 

29.7

 

12.5

Net earnings per share (Diluted)

$          2.59

     

$          2.30

     

12.6

Effective tax rate

16.5

%

   

15.0

%

     
                   

(1) See Reconciliation of Non-GAAP Financial Measures.

                 

 

 

 

Johnson & Johnson and Subsidiaries

       

Reconciliation of Non-GAAP Financial Measures 

       
     

First Quarter

 

(Dollars in Millions Except Per Share Data)

 

2021

 

2020

 

Net Earnings, after tax- as reported

 

$6,197

 

$5,796

           
 

Pre-tax Adjustments 

       
 

Intangible Asset Amortization expense

 

1,215

 

1,118

 

Litigation expense

 

-

 

120

 

Restructuring related

 

104

 

118

 

Acquisition, integration and divestiture related 1

 

(538)

 

(962)

 

Unrealized (gains)/losses on securities 

 

35

 

327

 

Medical Device Regulation 

 

46

 

14

           
 

Tax Adjustments

       
 

Tax impact on special item adjustments2

 

(113)

 

(267)

 

Tax legislation and other tax related

 

(22)

 

(110)

 

Adjusted Net Earnings, after tax

 

$6,924

 

$6,154

 

Average shares outstanding (Diluted)

 

2,672.7

 

2,671.0

 

Adjusted net earnings per share (Diluted)

 

$2.59

 

$2.30

 

Operational adjusted net earnings per share (Diluted)

 

$2.49

   
           
 

Notes:

       

1

Acquisition, integration and divestiture related for the first quarter of 2021 primarily includes the gain on the divestiture of 2
Pharmaeutical brands outside of the U.S.  The first quarter of 2020 primarily includes a $983M Contingent Consideration reversal
related to the timing of certain developmental milestones associated with the Auris Health acquisition. 

2

The tax impact related to special item adjustments reflects the current and deferred income taxes associated with the above pre-tax
special items in arriving at adjusted earnings.

   

 

 

Johnson & Johnson and Subsidiaries

               

Reconciliation of Non-GAAP Financial Measure

               
                 

Adjusted Operational Sales Growth

 FIRST QUARTER 2021 ACTUAL vs. 2020 ACTUAL 

 

 Segments 

   

 Consumer Health 

 

 Pharmaceutical 

 

 Medical Devices 

 

 Total 

 WW As Reported 

 

(2.3)%

 

9.6%

 

10.9%

 

7.9%

 U.S. 

 

(7.4)%

 

6.4%

 

5.4%

 

3.9%

 International 

 

2.5%

 

13.4%

 

16.2%

 

12.2%

                 

 WW Currency 

 

1.0

 

2.5

 

2.9

 

2.4

 U.S. 

 

-

 

-

 

-

 

-

 International 

 

2.0

 

5.5

 

5.7

 

4.9

                 

 WW Operational 

 

(3.3)%

 

7.1%

 

8.0%

 

5.5%

 U.S. 

 

(7.4)%

 

6.4%

 

5.4%

 

3.9%

 International 

 

0.5%

 

7.9%

 

10.5%

 

7.3%

                 

General Surgery

               

Advanced Sterilization Products

         

0.6

 

0.2

 U.S. 

         

0.0

 

0.0

 International 

         

1.2

 

0.4

                 

All Other Acquisitions and Divestitures

 

0.4

 

0.3

 

0.1

 

0.3

 U.S. 

 

0.5

 

(0.2)

 

0.2

 

0.0

 International 

 

0.4

 

0.9

 

0.0

 

0.5

                 

WW Adjusted Operational

 

(2.9)%

 

7.4%

 

8.8%

 

6.0%

 U.S. 

 

(6.9)%

 

6.2%

 

5.6%

 

3.9%

 International 

 

0.9%

 

8.8%

 

11.8%

 

8.2%

                 

Note: Percentages are based on actual, non-rounded figures and may not sum

   
 

 

 

   

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

 
 

FIRST QUARTER

   
         

% Change

   
   

2021

 

2020

Reported

Operational (1)

Currency

   

CONSUMER HEALTH SEGMENT (2) 

                 

OTC

                 

US

 

$              599

 

689

-13.0%

-13.0%

-

   

Intl

 

575

 

659

-12.8%

-16.6%

3.8%

   

WW

 

1,175

 

1,348

-12.9%

-14.8%

1.9%

   

SKIN HEALTH / BEAUTY

                 

US

 

634

 

659

-3.9%

-3.9%

-

   

Intl

 

529

 

458

15.7%

12.3%

3.4%

   

WW

 

1,163

 

1,117

4.1%

2.8%

1.3%

   

ORAL CARE

                 

US

 

163

 

176

-7.2%

-7.2%

-

   

Intl

 

254

 

219

16.0%

13.9%

2.1%

   

WW

 

417

 

395

5.7%

4.5%

1.2%

   

BABY CARE

                 

US

 

96

 

92

4.2%

4.2%

-

   

Intl

 

293

 

269

8.9%

11.3%

-2.4%

   

WW

 

389

 

361

7.7%

9.5%

-1.8%

   

WOMEN'S HEALTH

                 

US

 

3

 

4

-25.8%

-25.8%

-

   

Intl

 

219

 

228

-3.9%

-2.2%

-1.7%

   

WW

 

222

 

232

-4.3%

-2.6%

-1.7%

   

WOUND CARE / OTHER

                 

US

 

115

 

119

-3.0%

-3.0%

-

   

Intl

 

61

 

52

17.6%

14.2%

3.4%

   

WW

 

177

 

171

3.3%

2.2%

1.1%

   
                   

TOTAL CONSUMER HEALTH

                 

US

 

1,611

 

1,740

-7.4%

-7.4%

-

   

Intl

 

1,932

 

1,885

2.5%

0.5%

2.0%

   

WW

 

$           3,543

 

3,625

-2.3%

-3.3%

1.0%

   
                   
                   

See footnotes at end of schedule

                 
                   
                   
                   
   

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

 

FIRST QUARTER

   
         

% Change

   

PHARMACEUTICAL SEGMENT (2,3)

 

2021

 

2020

Reported

Operational (1)

Currency

   
                   

IMMUNOLOGY

                 

US

 

$           2,413

 

2,410

0.1%

0.1%

-

   

Intl

 

1,501

 

1,228

22.3%

15.9%

6.4%

   

WW

 

3,914

 

3,638

7.6%

5.5%

2.1%

   

REMICADE

                 

US 

 

489

 

625

-21.7%

-21.7%

-

   

US Exports (4)

 

57

 

110

-48.4%

-48.4%

-

   

Intl

 

232

 

256

-9.4%

-12.1%

2.7%

   

WW

 

777

 

990

-21.5%

-22.2%

0.7%

   

SIMPONI / SIMPONI ARIA

                 

US

 

255

 

272

-5.9%

-5.9%

-

   

Intl

 

307

 

258

18.9%

13.8%

5.1%

   

WW

 

562

 

529

6.2%

3.7%

2.5%

   

STELARA

                 

US

 

1,331

 

1,217

9.4%

9.4%

-

   

Intl

 

817

 

603

35.6%

27.6%

8.0%

   

WW

 

2,148

 

1,819

18.1%

15.4%

2.7%

   

TREMFYA

                 

US

 

274

 

187

46.3%

46.3%

-

   

Intl

 

143

 

109

32.0%

23.1%

8.9%

   

WW

 

418

 

296

41.0%

37.8%

3.2%

   

OTHER IMMUNOLOGY

                 

US

 

7

 

-

*

*

-

   

Intl

 

2

 

3

-38.4%

-36.3%

-2.1%

   

WW

 

8

 

3

*

*

*

   

INFECTIOUS DISEASES

                 

US

 

512

 

436

17.4%

17.4%

-

   

Intl

 

494

 

483

2.3%

-2.2%

4.5%

   

WW

 

1,007

 

920

9.5%

7.1%

2.4%

   

COVID-19 VACCINE

                 

US

 

100

 

-

*

*

-

   

Intl

 

-

 

-

-

-

-

   

WW

 

100

 

-

*

*

-

   

EDURANT / rilpivirine

                 

US

 

10

 

12

-12.3%

-12.3%

-

   

Intl

 

233

 

212

9.8%

0.9%

8.9%

   

WW

 

243

 

224

8.6%

0.2%

8.4%

   

PREZISTA / PREZCOBIX / REZOLSTA / SYMTUZA

                 

US

 

380

 

396

-3.8%

-3.8%

-

   

Intl

 

166

 

184

-9.9%

-10.4%

0.5%

   

WW

 

546

 

579

-5.8%

-5.9%

0.1%

   

OTHER INFECTIOUS DISEASES

                 

US

 

21

 

29

-27.0%

-27.0%

-

   

Intl

 

96

 

87

9.7%

7.4%

2.3%

   

WW

 

117

 

116

0.6%

-1.2%

1.8%

   
                   
                   
                   
   

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

 
 

FIRST QUARTER

   
         

% Change

   
   

2021

 

2020

Reported

Operational (1)

Currency

   

NEUROSCIENCE

                 

US

 

771

 

748

3.2%

3.2%

-

   

Intl

 

949

 

910

4.3%

0.4%

3.9%

   

WW

 

1,721

 

1,658

3.8%

1.6%

2.2%

   

CONCERTA / Methylphenidate

                 

US

 

47

 

52

-9.6%

-9.6%

-

   

Intl

 

123

 

118

4.5%

-0.4%

4.9%

   

WW

 

171

 

171

0.2%

-3.2%

3.4%

   

INVEGA SUSTENNA / XEPLION /
INVEGA TRINZA / TREVICTA

                 

US

 

589

 

544

8.3%

8.3%

-

   

Intl

 

376

 

339

11.0%

4.5%

6.5%

   

WW

 

965

 

883

9.4%

6.9%

2.5%

   

RISPERDAL CONSTA

                 

US

 

67

 

76

-11.8%

-11.8%

-

   

Intl

 

89

 

94

-4.8%

-8.8%

4.0%

   

WW

 

157

 

170

-7.9%

-10.1%

2.2%

   

OTHER NEUROSCIENCE

                 

US

 

67

 

75

-9.8%

-9.8%

-

   

Intl

 

361

 

360

0.2%

-0.9%

1.1%

   

WW

 

428

 

435

-1.5%

-2.5%

1.0%

   

ONCOLOGY

                 

US

 

1,377

 

1,175

17.2%

17.2%

-

   

Intl

 

2,193

 

1,839

19.3%

12.9%

6.4%

   

WW

 

3,570

 

3,013

18.5%

14.6%

3.9%

   

DARZALEX

                 

US

 

691

 

463

49.2%

49.2%

-

   

Intl

 

674

 

474

42.2%

35.3%

6.9%

   

WW

 

1,365

 

937

45.6%

42.2%

3.4%

   

ERLEADA

                 

US

 

171

 

119

44.0%

44.0%

-

   

Intl

 

90

 

24

*

*

*

   

WW

 

261

 

143

82.8%

79.7%

3.1%

   

IMBRUVICA

                 

US

 

444

 

432

2.8%

2.8%

-

   

Intl

 

680

 

599

13.5%

7.6%

5.9%

   

WW

 

1,125

 

1,031

9.0%

5.6%

3.4%

   

ZYTIGA / abiraterone acetate

                 

US

 

50

 

139

-64.2%

-64.2%

-

   

Intl

 

588

 

552

6.6%

0.0%

6.6%

   

WW

 

638

 

690

-7.6%

-12.9%

5.3%

   

OTHER ONCOLOGY(5)

                 

US

 

21

 

22

-5.1%

-5.1%

-

   

Intl

 

161

 

190

-15.3%

-19.3%

4.0%

   

WW

 

182

 

212

-14.2%

-17.9%

3.7%

   
                   
                   
                   
   

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

   
 

FIRST QUARTER

   
         

% Change

   
   

2021

 

2020

Reported

Operational (1)

Currency

   

PULMONARY HYPERTENSION

                 

US

 

573

 

486

18.0%

18.0%

-

   

Intl

 

288

 

260

10.8%

5.6%

5.2%

   

WW

 

861

 

745

15.5%

13.7%

1.8%

   

OPSUMIT

                 

US

 

272

 

229

18.5%

18.5%

-

   

Intl

 

179

 

160

11.5%

6.3%

5.2%

   

WW

 

450

 

389

15.6%

13.5%

2.1%

   

UPTRAVI

                 

US

 

259

 

212

21.9%

21.9%

-

   

Intl

 

46

 

38

23.0%

15.7%

7.3%

   

WW

 

305

 

250

22.0%

20.9%

1.1%

   

OTHER PULMONARY HYPERTENSION

                 

US

 

42

 

44

-3.5%

-3.5%

-

   

Intl

 

63

 

62

1.4%

-2.1%

3.5%

   

WW

 

105

 

106

-0.6%

-2.7%

2.1%

   

CARDIOVASCULAR / METABOLISM / OTHER

                 

US

 

799

 

806

-0.9%

-0.9%

-

   

Intl

 

328

 

354

-7.2%

-11.3%

4.1%

   

WW

 

1,127

 

1,160

-2.8%

-4.1%

1.3%

   

XARELTO

                 

US

 

589

 

527

11.7%

11.7%

-

   

Intl

 

-

 

-

-

-

-

   

WW

 

589

 

527

11.7%

11.7%

-

   

INVOKANA / INVOKAMET

                 

US

 

87

 

117

-26.1%

-26.1%

-

   

Intl

 

63

 

58

9.2%

4.2%

5.0%

   

WW

 

150

 

175

-14.4%

-16.1%

1.7%

   

PROCRIT / EPREX

                 

US

 

62

 

76

-18.3%

-18.3%

-

   

Intl

 

64

 

79

-18.1%

-22.2%

4.1%

   

WW

 

127

 

155

-18.2%

-20.3%

2.1%

   

OTHER

                 

US

 

60

 

85

-28.8%

-28.8%

-

   

Intl

 

201

 

217

-7.7%

-11.5%

3.8%

   

WW

 

261

 

302

-13.6%

-16.4%

2.8%

   

TOTAL PHARMACEUTICAL

                 

US

 

6,446

 

6,061

6.4%

6.4%

-

   

Intl

 

5,753

 

5,073

13.4%

7.9%

5.5%

   

WW

 

$         12,199

 

11,134

9.6%

7.1%

2.5%

   
                   

See footnotes at end of schedule

                 
                   
                   
                   
                   
   

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

   
 

FIRST QUARTER

   
         

% Change

   

MEDICAL DEVICES SEGMENT (2)

 

2021

 

2020

Reported

Operational (1)

Currency

   
                   

INTERVENTIONAL SOLUTIONS

                 

US

 

$              434

 

365

19.0%

19.0%

-

   

Intl

 

514

 

362

42.0%

34.0%

8.0%

   

WW

 

949

 

727

30.4%

26.4%

4.0%

   

ORTHOPAEDICS

                 

US 

 

1,249

 

1,250

-0.1%

-0.1%

-

   

Intl

 

864

 

788

9.7%

3.1%

6.6%

   

WW

 

2,113

 

2,038

3.7%

1.2%

2.5%

   

HIPS

                 

US

 

210

 

206

2.4%

2.4%

-

   

Intl

 

146

 

132

11.2%

4.5%

6.7%

   

WW

 

357

 

337

5.8%

3.2%

2.6%

   

KNEES

                 

US

 

185

 

214

-13.5%

-13.5%

-

   

Intl

 

132

 

130

2.0%

-4.1%

6.1%

   

WW

 

317

 

343

-7.6%

-9.9%

2.3%

   

TRAUMA

                 

US

 

450

 

407

10.7%

10.7%

-

   

Intl

 

282

 

247

14.4%

7.7%

6.7%

   

WW

 

733

 

654

12.1%

9.5%

2.6%

   

SPINE, SPORTS & OTHER

                 

US

 

403

 

423

-4.8%

-4.8%

-

   

Intl

 

303

 

280

8.4%

1.7%

6.7%

   

WW

 

706

 

703

0.4%

-2.2%

2.6%

   
                   
                   
                   
                   
   

 

REPORTED SALES vs. PRIOR PERIOD ($MM)

   
 

FIRST QUARTER

   
         

% Change

   
   

2021

 

2020

Reported

Operational (1)

Currency

   

SURGERY

                 

US

 

898

 

844

6.5%

6.5%

-

   

Intl

 

1,474

 

1,257

17.3%

11.7%

5.6%

   

WW

 

2,372

 

2,100

12.9%

9.6%

3.3%

   

ADVANCED

                 

US

 

405

 

381

6.5%

6.5%

-

   

Intl

 

713

 

567

25.7%

19.5%

6.2%

   

WW

 

1,118

 

948

18.0%

14.3%

3.7%

   

GENERAL

                 

US

 

493

 

463

6.5%

6.5%

-

   

Intl

 

761

 

690

10.3%

5.3%

5.0%

   

WW

 

1,254

 

1,153

8.8%

5.8%

3.0%

   

VISION

                 

US

 

472

 

439

7.4%

7.4%

-

   

Intl

 

673

 

628

7.3%

3.9%

3.4%

   

WW

 

1,145

 

1,067

7.3%

5.4%

1.9%

   

CONTACT LENSES / OTHER

                 

US

 

371

 

346

7.2%

7.2%

-

   

Intl

 

486

 

467

4.0%

0.9%

3.1%

   

WW

 

857

 

814

5.3%

3.5%

1.8%

   

SURGICAL

                 

US

 

101

 

93

8.2%

8.2%

-

   

Intl

 

187

 

160

17.0%

12.9%

4.1%

   

WW

 

288

 

253

13.7%

11.2%

2.5%

   
                   

TOTAL MEDICAL DEVICES

                 

US

 

3,054

 

2,898

5.4%

5.4%

-

   

Intl

 

3,525

 

3,034

16.2%

10.5%

5.7%

   

WW

 

$           6,579

 

5,932

10.9%

8.0%

2.9%

   
                   
                   

Note: Columns and rows within tables may not add due to rounding. Percentages have been calculated using actual, non-rounded figures and,
 therefore, may not recalculate precisely.

                   

* Percentage greater than 100% or not meaningful

             

(1) Operational growth excludes the effect of translational currency

         

(2) Unaudited

                 

(3) Certain prior year amounts have been reclassified to conform to current year product disclosures

     

(4) Reported as U.S. sales

                 

(5) Refer to supplemental schedule

                 

 

                                     

Supplemental Sales Information
 

(Dollars in Millions)

Prior quarter amounts have been reclassified to 

conform to current quarter product disclosure

   

2019

 

2020

 

2020

 
                                   
 

PHARMACEUTICAL SEGMENT(1)

 

Full Year

     

Q1

 

Q2

 

Q3

 

Q4

   

Full Year

   
 

Oncology

                                 
 

OTHER ONCOLOGY(2)

                                 
 

US

 

70

     

22

 

20

 

21

 

20

   

83

   
 

Intl

 

1,087

     

190

 

185

 

181

 

183

   

738

   
 

WW

 

1,158

     

212

 

204

 

203

 

202

   

821

   
                                     
                                     
                                     
 

Note: Columns and rows within tables may not add due to rounding. 

                     
                                     
 

(1) Unaudited

                                 
 

(2) Other Oncology is inclusive of VELCADE, which was previously disclosed separately

                 

 

(PRNewsfoto/Johnson & Johnson)

 

 

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/johnson--johnson-reports-2021-first-quarter-results-301272130.html

SOURCE Johnson & Johnson

Press: Christina Chan (732) 524-6297; Courtney Dugan (347) 452-1061; Investor Contacts: Christopher DelOrefice (732) 524-2955; Sarah Wood (732) 524-2617

This site uses cookies as described in our Cookie Policy Please click the "Accept" button or continue to use our site if you agree to our use of cookies.